SYShun Yamamoto

Shun Yamamoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shun Yamamoto has a total of 115 co-authors. Here are the top co-authors by number of shared publications:

  • Ken Kato

    Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

    10 shared publications
  • Ken Kato

    Department of Head & Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

    3 shared publications
  • Yuko Kitagawa

    Department of Surgery, Keio University, School of Medicine, Tokyo, Japan

    3 shared publications
  • Hiroyuki Daiko

    Department of Esophageal Surgery, National Cancer Center Hospital, Tokyo, Japan

    2 shared publications
  • Takashi Kojima

    Department of Gastroenterology & Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan

    2 shared publications
  • Tetsuya Abe

    Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya, Japan

    2 shared publications

Latest Publications

  • Chemotherapy, Immunotherapy, and Chemoradiotherapy

    by Shun Yamamoto, Hiroshi Imazeki, Ken Kato

  • Top Cited Papers
    Open Access

    Clinical role of anti-PD-1 immunotherapies in esophageal cancer

    by Momoko Sano, Hiroshi Imazeki, Shun Yamamoto, Ken Kato

    Anti-PD-1 antibodies in pharmacotherapy for esophageal cancer have caused a paradigm shift in the treatment strategy. New evidence is being generated not only for metastatic or recurrent cases, but also in the perioperative setting, and the role of anti-PD-1 antibodies in the treatment of esophageal cancer will continue to increase. This review summarizes the clinical role of approved anti-PD-1 antibodies, including nivolumab and pembrolizumab, and discusses additional agents supported by phase 3 evidence. We emphasize current standards of care across metastatic and perioperative settings while briefly addressing emerging strategies under clinical evaluation. Anti-PD-1 antibodies containing therapies have become central to ESCC management, improving survival in both metastatic and perioperative settings. Regional phase 3 trials have expanded therapeutic options, although differences in regulatory approval influence global accessibility. Despite these advances, optimal patient selection remains challenging, and predictive biomarkers are urgently needed. Future progress will depend on biomarker development, treatment sequencing, and integration of emerging strategies supported by robust clinical evidence.


  • Open Access

    ISDE guidelines on the management of cT2N0 esophageal cancer

    by Geoffrey P Kohn, Virginia Litle, Yousif Eliya, Samantha Leng, Mohammad Asghari-Jafarabadi, Nicolas Contreras, Andrew Davies, Rudy Lackner, Kimberley S Mak, Tom Mala, et al.

    Esophageal cancer incidence is rising globally, with at least 500,000 new cases diagnosed annually. Management options for non-metastatic disease include primary resection, neoadjuvant or perioperative therapies, or definitive non-surgical treatment, with the choice being guided by tumor staging, histology, patient fitness, and available resources. However, even with the use of advanced diagnostic modalities, preoperative clinical staging is challenging with respect to accuracy of both tumor and nodal assessment. Early-stage esophageal cancer may be managed with local therapies, such as endoscopic mucosal resection or submucosal dissection, while for more advanced tumors managed with curative intent neoadjuvant oncologic therapy is commonly recommended. However, between these two groups lies an infrequent but important subgroup of patients, clinically staged cT2N0M0 esophageal cancer. Guidelines such as the NIH’s National Cancer Institute recommends either surgery alone or neoadjuvant therapy followed by surgery for AJCC Stage I cancers, and add the option of definitive chemoradiation for Stage II disease. With cT2N0 disease straddling both AJCC classifications, management guidance is lacking. This guideline will provide an evidence-based recommendation from the International Society For Disease Of The Esophagus on the management of cT2N0 esophageal cancer, of all types. The recommendations are intended to support surgeons, oncologists, and patients in decisions about the best practice preoperative oncologic management of cT2N0M0 esophageal cancer. A Working Group within the International Society for Diseases of the Esophagus (ISDE) Guidelines Committee performed a systematic review of the literature. Results of the systematic review were presented to a panel of experts and these results informed the panel discussion about the guideline. This panel used Grading of Recommendations Assessment, Development, and Evaluation approach to deliberate and formulate recommendations. The panel agreed on a conditional recommendation for the use of neoadjuvant therapy followed by surgery over primary surgical resection (PSR) for adult patients with cT2N0M0 esophageal cancer. Preoperative clinical staging of esophageal cancer is uncertain, with deficiencies in all diagnostic modalities. However, when all modern staging techniques are utilized, the ISDE recommends neoadjuvant therapy followed by surgical resection as the favored treatment of cT2N0 esophageal cancer. Certain patient groups may still be offered PSR, particularly those unable to tolerate neoadjuvant therapies, or those patients with very low risk of lymph node metastasis as suggested by histological features, small tumor size, and other features.

  • Tislelizumab for the treatment of advanced esophageal squamous cell carcinoma

    by Kazuhiro Shiraishi, Shun Yamamoto, Ken Kato

    Advanced esophageal squamous cell carcinoma (ESCC) patients had poor prognosis and few effective drugs based on the randomized controlled trials (RCTs). In such a circumstance, recent RCTs have shown the clinical efficacy of immune checkpoint inhibitors (ICIs) as first- or second-line treatment for advanced ESCC patients. Tislelizumab is one of the anti-Programmed-Death-1 (PD-1) antibodies; at first, tislelizumab monotherapy showed clinical efficacy as a second-line treatment for advanced ESCC patients based on the results of the RATIONALE-302 trial. Since then, tislelizumab plus doublet chemotherapy has shown superiority in overall survival compared to doublet chemotherapy for untreated advanced ESCC patients in the RATIONALE-306 trial. In this review, we share the overview of the development of tislelizumab and discuss the future perspectives on ICIs for advanced ESCC patients. In our opinion, tislelizumab plus doublet chemotherapy is one of the first-line standard treatments for advanced ESCC patients regardless of Programmed cell Death ligand 1 expression. Some other ICI-containing treatments showed clinical efficacy for untreated ESCC patients; we need further investigation to select these treatments appropriately.


  • Open Access

    Quantifying CD73 expression after chemotherapy or chemoradiotherapy in esophageal squamous cell carcinoma

    by Zachary A. Cooper, Ying Wang, Philip L. Martin, Kosho Murayama, Rakesh Kumar, Ken Kato, Shun Yamamoto, Shigeki Sekine

    Background: CD73 and CD39, key components of the adenosine axis, are expressed in multiple malignancies; the impact of standard-of-care treatment on their expression and antitumor immunity in esophageal squamous cell carcinoma (ESCC) remains unclear. We evaluated the adenosine axis in the context of neoadjuvant therapy received and its relationship to immune markers in ESCC tumor samples. Methods: Samples from patients who underwent surgical resection at the National Cancer Center Hospital, Tokyo, Japan, between January 2002 and July 2019 following no neoadjuvant therapy (n = 55; treatment-naïve), chemotherapy (n = 200), or chemoradiotherapy (CRT; n = 20) were immunohistochemically stained for CD73, CD39, PD-L1, FoxP3, and CD8; markers were quantified across tumor microenvironment (TME) compartments. Results: Median CD73 TME expression was lower in the treatment-naïve (2.8%) versus chemotherapy (7.2%; p < 0.0001) and CRT (6.4%; p < 0.01) cohorts, most profoundly in the stroma (median 4.1% vs 9.4% [p < 0.0001] and 8.1% [p < 0.01]). Median intraepithelial CD8-positive cell density was higher in the treatment-naïve (200.7 cells/mm2) versus chemotherapy (93.9 cells/mm2; p < 0.0001) and CRT (30.5 cells/mm2; p < 0.001) cohorts. Three-year recurrence-free survival (RFS) was 73.0%, 58.0%, and 30.0%, and 3-year overall survival (OS) was 78.2%, 71.4%, and 33.5%, in the treatment-naïve, chemotherapy, and CRT cohorts, respectively. High versus low CD73 TME expression was prognostic for longer RFS (treatment-naïve cohort: hazard ratio [HR] 0.16, 95% confidence interval [CI] 0.05–0.58, p = 0.0014; chemotherapy cohort: HR 0.52, 95% CI 0.34–0.78, p = 0.0012) and OS. Conclusions: These translational data demonstrating higher CD73 expression in tumors after neoadjuvant chemotherapy or CRT support potential combination strategies with CD73-targeted treatment in ESCC.


  • Open Access

    Analysis of Inertial Measurement Unit Data for an AI-Based Physical Function Assessment System Using In-Clinic-like Movements

    by Nobuji Kouno, Satoshi Takahashi, Ken Takasawa, Masaaki Komatsu, Naoaki Ishiguro, Katsuji Takeda, Ayumu Matsuoka, Maiko Fujimori, Kazuki Yokoyama, Shun Yamamoto, et al.

    Assessing objective physical function in patients with cancer is crucial for evaluating their ability to tolerate invasive treatments. Current assessment methods, such as the timed up and go (TUG) test and the short physical performance battery, tend to require additional resources and time, limiting their practicality in routine clinical practice. To address these challenges, we developed a system to assess physical function based on movements observed during clinical consultations and aimed to explore relevant features from inertial measurement unit data collected during those movements. As for the flow of the research, we first collected inertial measurement unit data from 61 patients with cancer while they replicated a series of movements in a consultation room. We then conducted correlation analyses to identify keypoints of focus and developed machine learning models to predict the TUG test outcomes using the extracted features. Regarding results, pelvic velocity variability (PVV) was identified using Lasso regression. A linear regression model using PVV as the input variable achieved a mean absolute error of 1.322 s and a correlation of 0.713 with the measured TUG results during five-fold cross-validation. Higher PVV correlated with shorter TUG test results. These findings provide a foundation for the development of an artificial intelligence-based physical function assessment system that operates without the need for additional resources.

  • Factors influencing decision-making between surgery and chemoradiotherapy for esophageal carcinoma from the JCOG0502

    by Shun Yamamoto, Ken Kato, Hiroyuki Daiko, Yoshinori Ito, Takeshi Kajiwara, Takashi Kojima, Hiroshi Miyata, Satoru Nakagawa, Masaki Ueno, Masaya Watanabe, et al.

    Aim: Treatment options for esophageal squamous cell carcinoma includes surgery and chemoradiotherapy (CRT), however there was limited information about the factors influenced in patients' decision-making.Materials & methods: Patients who participated in JCOG0502, a parallel group controlled trial comparing surgery with CRT, were analyzed for the factors related to decision-making.Results: Of the 368 patients (pts) enrolled in the nonrandomized part in JCOG0502, 209 pts opted for surgery and 159 pts chose CRT on their own. Background characteristics were the same except for age. Multivariable logistic regression analysis showed that age ≥65 years, male sex, multiple lesions, absence of children and doctor's thinking were associated with the selection of CRT.Conclusion: The doctor's option was the most influential factor in the patient's decision-making process.Clinical Trial Registration: UMIN000000551 (ClinicalTrials.gov).


  • Open Access

    Development of perioperative immune checkpoint inhibitor therapy for locally advanced esophageal squamous cell carcinoma

    by Toru Kadono, Shun Yamamoto, Ken Kato

    The standard preoperative treatment for resectable locally advanced esophageal squamous cell carcinoma (ESCC) is chemoradiotherapy in western countries (based on the CROSS trial) and triplet chemotherapy in Japan (based on the JCOG1109 trial). Postoperative nivolumab has recently been shown to improve disease-free survival in resectable locally advanced esophageal cancer after preoperative chemoradiotherapy in patients who had residual pathological disease, based on the CheckMate 577 trial. Furthermore, preoperative immune checkpoint inhibitor-containing treatments have also been developed. The JCOG1804E trial is presently evaluating the safety and efficacy of preoperative nivolumab-containing chemotherapy for resectable locally advanced ESCC. This review discusses the treatment of resectable locally advanced ESCC and future perspectives on perioperative immune checkpoint inhibitor-containing treatments.


  • Open Access

    Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma

    by Go Ikeda, Jun Miyakoshi, Shun Yamamoto, Ken Kato

    Esophageal cancer (EC) is the eighth most common cancer worldwide. In view of biology and anatomical restrictions, multimodality treatment strategies have been developed for EC. However, the progno... Tweetable abstract Advanced esophageal cancer has a poor prognosis that has improved with nivolumab-containing therapy. This review provides an overview of nivolumab-containing therapy for various ...


  • Open Access

    Protocol digest of a randomized controlled Phase III study comparing surgery alone versus adjuvant nivolumab versus adjuvant S-1 for locally advanced oesophageal squamous cell carcinoma with no pathological complete response after neoadjuvant chemotherapy followed by curative esophagectomy: Japan Clinical Oncology Group study JCOG2206 (SUNRISE Trial)

    by Ryosuke Kita, Satoru Matsuda, Motoo Nomura, Ryunosuke Machida, Keita Sasaki, Ken Kato, Rei Goto, Takashi Yoshioka, Shun Yamamoto, Takahiro Tsushima, et al.

    Although the efficacy of postoperative therapy with nivolumab after preoperative chemoradiotherapy for locally advanced oesophageal cancer has been proven in Western countries, the survival benefits of postoperative therapy after preoperative chemotherapy with docetaxel, cisplatin and 5-FU or cisplatin plus 5-FU as the Japanese standard therapy remain controversial. This randomized Phase III trial was designed to confirm the superiority of postoperative therapy with nivolumab over observation alone and S-1 over observation alone in patients with locally advanced oesophageal squamous cell carcinoma with no pathological complete response after preoperative chemotherapy followed by curative esophagectomy. A total of 450 patients will be enrolled from 56 hospitals in Japan over 5.5 years. The primary endpoint is relapse-free survival, and the secondary endpoints are disease-free survival, overall survival, adverse events and incremental cost-effectiveness ratio. This trial has been registered in the Japan Registry of Clinical Trials as jRCTs031230219 (https://jrct.niph.go.jp/latest-detail/jRCTs031230219).